SCHEMBL7206380

SCHEMBL7206380

COc1ccc(C(O[C@H]2C[C@H](n3cnc4c(NC(=O)c5ccccc5)ncnc43)O[C@@H]2COP(OCCC#N)N(C(C)C)C(C)C)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.35
TYMP P19971 2/20 0.34
P2RY12 Q9H244 2/20 0.34
GAPDH P04406 1/20 0.34
PRKAG1 P54619 1/20 0.34
PRKAA1 Q13131 1/20 0.34
PRKAB1 Q9Y478 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2054229 0.92 TYMP (0.39) PRMT6TYMPP2RY12GAPDHPRKAG1
SCHEMBL29449394 0.92 TYMP (0.39) PRMT6TYMPP2RY12GAPDHPRKAG1
SCHEMBL15786367 0.92 TYMP (0.39) PRMT6TYMPP2RY12GAPDHPRKAG1
SCHEMBL29674590 0.92 TYMP (0.39) PRMT6TYMPP2RY12GAPDHPRKAG1
SCHEMBL30448691 0.88 PRMT6 (0.39) PRMT6TYMPP2RY12GAPDHPRKAG1
SCHEMBL26347688 0.88 PRMT6 (0.39) PRMT6TYMPP2RY12GAPDHPRKAG1
SCHEMBL23881919 0.87 PRMT6 (0.34) PRMT6GAPDHPRKAG1PRKAA1PRKAB1
SCHEMBL24115324 0.87 TYMP (0.39) PRMT6TYMPP2RY12PRKAG1PRKAA1
SCHEMBL441412 0.87 ADORA2A (0.35) PRMT6P2RY12PRKAG1PRKAA1PRKAB1
SCHEMBL17231772 0.86 P2RY12 (0.37) PRMT6P2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030203356-A1 RNase L activator-antisense complexes THE CLEVELAND CLINIC FOUNDATION (US) 2003-10-30 US disclosed
US-6214805-B1 GENES, GENE SIGNALS, GENOMES RNA STRANDS AND RESPIRATORY SYNCYTIAL VIRUS WITH PROMOTERS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 2001-04-10 US disclosed
EP-1007655-A1 RNASE L ACTIVATORS AND ANTISENSE OLIGONUCLEOTIDES EFFECTIVE TO TREAT RSV INFECTIONS NATIONAL INSTITUTES OF HEALTH (US) 2000-06-14 EP disclosed
US-5998602-A RNase L activators and antisense oligonucleotides effective to treat RSV infections THE CLEVELAND CLINIC FOUINDATION AND GOVERNMENT (US) 1999-12-07 US disclosed